It makes you feel full more quickly and keeps you full for longer, making it easier to eat less
Rising Investment in Diabetes and Obesity Research The surge in investment for research and development in diabetes and obesity is a significant driver for the GLP-1 Drug Market
As of mid-2026, the company carries over 2,300 prescription products delivered by mail to patients nationwide, and is actively working with trade name manufacturers to add both single-source brands and specialty biologics to its pharmacy
However, with the more recently introduced SGLT2 inhibitors and GLP-1 receptor agonists having shown impressive cardiovascular risk reduction in addition to glycemic control efficacy, these newer agents may also be considered as first-line therapies in patients with pre-existing cardiovascular or renal disease (Garber 2020)
Access, however, can be discouraging